NCT Number: NCT05127915
The objective of the study is to evaluate the safety and efficacy of the Adient absorbable filter for the prevention of pulmonary embolism (PE: blood clot in the lungs). PE claims the lives of over 100,000 Americans each year, more than breast cancer, traffic fatalities and HIV combined.
Pharmaceutical anticoagulation (blood thinners) that reduce blood clot formation represent the standard of care for treating patients at risk for PE. However, for people who are temporarily unable to use anticoagulants, such as those who have suffered major trauma or those who are scheduled for surgical procedures, inferior vena cava (IVC) filters are used to help protect against PE. These blood filters prevent large blood clots that originate in the deep veins of the legs (deep vein thrombosis (DVT)) from reaching your lungs causing a potentially life-threatening PE.
Conventional metal IVC filters have been proven effective at reducing the incidence of PE, however, most require retrieval. If not retrieved within a timely manner (months), they can perforate the IVC, impale nearby organs with their barbed struts, and cause blood clots.
In contrast, the Adient absorbable filter traps blood clots similar to conventional metal IVC filters, but following the 8 week protection period, the filter itself breaks down into carbon dioxide and water. Hence no filter retrieval is required and complications are less likely due to the shortened indwell time. Once blood clots are trapped in the absorbable filter, the body's thrombolytic enzymes dissolve the clots within weeks while the filter itself resorbs in 6 to 8 months. The absorbable filter is braided from absorbable suture that has been proven safe over 4 decades.
The question being addressed with the randomized controlled trial portion is whether the placement of the absorbable filter in addition to current best practice PE prevention (sequential compression machines, compression stockings, and anticoagulants when indicated) significantly reduces the incidence of clinically significant PE in high risk subjects.
The absorbable filter will be indicated for the temporary prevention of PE in patients with transient high risk for venous thromboembolism (DVT and/or PE) with or without venous thromboembolic disease and as an enhancement to pharmaceutical anticoagulation and mechanical prophylaxis.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Aged 18 years or older
Willing to comply with the specified follow-up requirements including contrast enhanced CTs for the 9-month duration of the study
For female subjects of childbearing potential: a negative pregnancy test within 48 hours prior to the implantation procedure
For the prophylactic cohort, high risk VTE denoted by either:
Caprini score > 8 for surgical ICU, Parvizi score ≥ 150 for TKA (total knee replacement), ISS score ≥ 24 for trauma.
For the therapeutic cohort, documented VTE per the following:
Pulmonary thromboembolism when anticoagulants are contraindicated, Failure of anticoagulant therapy in thromboembolic diseases, Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced.
Requirement of temporary PE protection (8 weeks) based on clinical judgment
Fully informed subject or caretaker consent having executed an Institutional Review Board (IRB) or approved informed consent.
Exclusion criteria
Expected high VTE risk to extend beyond 8 weeks.
Vena cava filter currently implanted
History of abdominal or pelvic radiation therapy
Previous IVC filter placement/retrieval within 6 months prior to randomization
Confirmed positive blood cultures within the last 48 hours if there is bacteremia
Known sensitivity to radiographic contrast medium that cannot be adequately prophylactically pre-medicated
Known allergy or intolerance to IVC filter materials (i.e. PDSII absorbable suture)
Pregnant, lactating, or plans to become pregnant during investigation follow-up period
Renal insufficiency (GFR < 60) or requiring renal replacement therapy
IVC effective diameter (D) <16 mm or >28 mm anywhere within L1-L4, D = √(AP*Lat)
Less than 7cm from inferior-most renal vein to the iliac vein confluence
Duplication of the IVC
Any thrombus or occlusion in IVC on pre-procedural CT cavogram
Life expectancy of < 12 months
Simultaneous participation in another investigative drug or device trial that has not reached its primary endpoint
Other co-morbid condition that, in the opinion of the Investigator, could limit the subject's ability to participate in or would affect the scientific integrity of the study
Previously enrolled in a clinical investigation of the Adient filter.
For Roll In, patient has advanced heart failure or recent (6 weeks) myocardial infarction. - - -
Advanced heart failure is defined by NYHA class IV or AHA/ACC/HFSA stage D or LVEF < 40%. Subjects with MI diagnosed with ECG alone without MI history and symptoms are not excluded.
Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
Time frame: 2 weeks for asymptomatic proximal PE screening and through 8 weeks for symptomatic PE
Clinically significant PE includes asymptomatic proximal PE screened at 2 weeks, in addition to symptomatic PE through 8 weeks post index event confirmed by computed tomography (CT) angiography. Proximal PE includes thrombus (blood clots) observed in the pulmonary trunk, main pulmonary arteries, or lobar arteries.
Time frame: 96 hours to 9 months depending on the safety parameter
Potential complications include: (a) caval thrombotic occlusion within 9 months, (b) all-filter embolization within 9 months, (c) serious filter-related complications within 9 months, (d) filter placement procedural related Series Adverse Events (SAE) within the perioperative period (96 hours), (e) filter placement vascular access site SAE within the perioperative period, (f) symptomatic PE subsequent to filter deployment within 9 months.
Time frame: 9 months overall duration
All DVT includes both symptomatic DVT and asymptomatic DVT screened at 2 weeks, 10 weeks and 9 months.
Time frame: 9 months
Potential complications include (a) new symptomatic PE through 8 weeks, (b) filter migration (> 2cm), (c) filter embolization, (d) caval perforation (> 5mm), (e) symptomatic caval thrombosis, and (f) any other symptomatic filter-related complication requiring invasive intervention, or filter related death.
Time frame: 8 weeks
Time frame: 9 months
Quantification of the occlusion of the pulmonary vascular bed from a PE.
Time frame: 10 weeks
Time frame: 9 months
Time frame: 2 weeks, 10 weeks, and 9 months
Detected on ultrasound.
Time frame: 2 weeks, 10 weeks, and 9 months
Detected on ultrasound.
Time frame: 9 months
Time frame: 9 months
Major bleeding defined by International Society on Thrombosis and Haemostases.
Adient Medical
Industry
A Prospective, Multicenter, Pivotal Study With Randomized Controlled Prophylactic and Independent Therapeutic Cohorts to Evaluate the Safety and Efficacy of an Absorbable Vena Cava Filter for Pulmonary Embolism Prevention
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00005152
Angina Pectoris, Brain Diseases
View Trial DetailsNCT06055920
Cardiovascular Diseases, Embolism
Birmingham, Alabama, United States
View Trial DetailsNCT04430569
Cardiovascular Diseases, Embolism
Linz, Austria
View Trial DetailsNCT05408546
Cardiovascular Diseases, Embolism
Phoenix, Arizona, United States
View Trial Details